Parmax Pharma share price
BSE: 540359Pharmaceuticals & BiotechnologySmall Cap
Last close ₹136.40down ₹1.35 (0.98%)
Share price at the BSE close on 19 Oct 2026. Previous close ₹137.75.
52-week range of traded prices to 19 Oct 2026
₹22.60Low, 25 Mar 2026₹139.10High, 5 Oct 2026
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹94 Cr4,411th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- −70.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day.
- 271
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 14 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹8.22 Crup 148.16%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹2.20 CrQuarter to Mar 2026: −₹0.58 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 26.8%
Revenue by year
Peak revenue ₹28 Cr, year to Mar 2025
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 5 of the 10 years shown
| ₹ crore | Sep 2024Filed 15 Nov | Dec 2024Filed 14 Feb | Mar 2025Filed 16 Jun | Jun 2025Filed 14 Aug | Sep 2025Filed 17 Nov | Dec 2025Filed 14 Feb | Mar 2026Filed 3 Jun | Jun 2026Filed 14 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.28 | 6.28 | 4.83 | 1.94 | 2.53 | 4.33 | 3.31 | 8.22 |
| Net profit | −0.22 | −0.39 | −1.49 | −0.76 | −2.08 | −0.73 | −0.58 | 2.20 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | −2.3% | −6.3% | −31.0% | −39.4% | −82.1% | −16.9% | −17.6% | 26.8% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, BULK DRUG AND DRUG INTERMEDIATES, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −32.7% | – | – | 0.0% |
| 3 years | −2.2% | – | – | 0.0% |
| 5 years | −4.3% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Parmax Pharma in market cap. Parmax Pharma's own figures are from its last trade, on 19 Oct 2026. 1 company in the table last traded before then: its row is priced on its last trade.
Parmax Pharma is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Alpa LaboratoriesALPA | 104 | – | 0.6 | – | +0.5% | – | – | −1.8% | 0.00% |
 Pharmaids PharmaceuticalsPHARMAID | 102 | – | 2.1 | – | +18.5% | – | −8.5% | −15.8% | 0.00% |
 Sotac PharmaceuticalsSOTAC | 102 | 17.6 | 1.7 | – | +0.1% | −28.2% | 10.3% | – | 0.22% |
 Veerhealth CareVEERHEALTH | 99 | 64.4 | 4.3 | 23.3 | +177.2% | +199.7% | 6.8% | 11.0% | 0.00% |
 Amwill Health CareAMWILL | 90 | 7.9 | 1.1 | – | +12.1% | +6.4% | 15.2% | – | 1.11% |
 Concord DrugsCONCORD | 90 | 43.7 | – | – | +82.5% | +380.5% | 5.0% | 7.1% | 0.00% |
 Vaishali PharmaVAISHALI | 90 | 20.2 | 1.3 | 25.2 | – | – | 6.6% | 4.2% | 0.00% |
 Mercury LaboratoriesMERCURYLAB | 88 | 21.1 | 1.5 | 11.3 | −3.7% | +10.4% | 7.5% | 7.0% | 0.48% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
28 Sep · Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015 - Intimation Of Fire Incident At The Plant Of The Company
Parmax Pharma share price by year
Each calendar year to 2025.Parmax Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 33.83 | −23.5% | 48.94 | 29.67 |
| 2024 | 44.25 | +35.9% | 51.66 | 25.90 |
| 2023 | 32.57 | −15.8% | 39.35 | 27.55 |
| 2022 | 38.70 | −35.4% | 61.95 | 27.15 |
| 2021 | 59.95 | +103.2% | 78.00 | 24.25 |
| 2020 | 29.50 | +63.9% | 49.90 | 15.20 |
| 2019 | 18.00 | +4.0% | 19.00 | 17.30 |
| 2018 | 17.30 | +1.8% | 21.25 | 17.00 |
| 2017 | 17.00 | – | 17.00 | 12.50 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 18 Feb 2020. 2019 is from its first session, 23 Apr 2019. 2018 is from its first session, 27 Feb 2018. 2017 is from its first session, 17 Mar 2017. The close is the year's last trade for 2019 (5 Dec 2019) and 2018 (28 Nov 2018).
Recent sessions
The last 10 trading days to 19 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 19 Oct 2026 | 136.40 | 136.40 | 136.40 | 136.40 | 136.40 | 271 |
| 12 Oct 2026 | 139.10 | 139.10 | 137.75 | 137.75 | 138.10 | 1,506 |
| 5 Oct 2026 | 137.75 | 139.10 | 136.40 | 139.10 | 138.03 | 12,921 |
| 28 Sep 2026 | 137.20 | 137.75 | 136.95 | 137.75 | 137.73 | 16,216 |
| 21 Sep 2026 | 136.40 | 136.40 | 136.40 | 136.40 | 136.40 | 3,917 |
| 15 Sep 2026 | 135.05 | 135.05 | 135.00 | 135.05 | 135.05 | 6,334 |
| 7 Sep 2026 | 133.75 | 133.75 | 133.75 | 133.75 | 133.75 | 2,018 |
| 31 Aug 2026 | 132.45 | 132.45 | 132.45 | 132.45 | 132.45 | 12,767 |
| 24 Aug 2026 | 131.15 | 131.15 | 131.15 | 131.15 | 131.15 | 54,997 |
| 21 Aug 2026 | 129.90 | 129.90 | 129.90 | 129.90 | 129.90 | 204 |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Parmax Pharma Limited
- BSE code
- 540359
- ISIN
- INE240T01014
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Mar 2017
- Face value
- ₹10
- CIN
- L24231GJ1994PLC023504
- Corporate identity number, the registrar of companies' code for it